Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries Health policies, systems and management in high-income countries

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Damm, Oliver ^a   Ultsch, Bernhard ^b   Horn, Johannes ^c   Mikolajczyk, Rafael T ^c,d   Greiner, Wolfgang ^a   Wichmann, Ole ^b  

^a BIELEFELD UNIVERSITY   (Germany)

^b ROBERT KOCH INSTITUTE   (Germany)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Cost effectiveness; Economic evaluation; Systematic review; Vaccination; Varicella; Zoster

Indexed keywords

CHICKENPOX VACCINE; VARICELLA ZOSTER VACCINE;

AGE; CHICKENPOX; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; ECONOMICS; HERPES ZOSTER; HUMAN; INCIDENCE; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; CHICKENPOX; CHICKENPOX VACCINE; COMMERCE; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; QUALITY-ADJUSTED LIFE YEARS;

EID: 84938994051     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1861-8     Document Type: Article

References (72)

1. Miller E, Marshall R, Vurdien J. Epidemiology, outcome and control of varicella-zoster infection. Rev Med Microbiol. 1993;4:222-30.
2. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A. Seroprevalence of varicella-zoster virus in the German population. Vaccine. 2002;20:121-4.
3. Schmader K. Herpes zoster and postherpetic neuralgie in older adults. Clin Geriatr Med. 2007;23:615-32.
4. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571-5.
5. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older oersons with postherpetic neuralgia: Results from a population-based survey. J Pain. 2005;6:356-63.
6. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain. 1996;67:241-51.
7. Bonanni P, Breuer J, Gershon A, Gershon M, Hryniewicz W, Papaevangelou V, Rentier B, Rümke H, Sadzot-Delvaux C, Senterre J, Weil-Olivier C, Wutzler P. Varicella vaccination in Europe - taking the practical approach. BMC Med. 2009;7:26.
8. Rentier B, Gershon AA. The Members of the European Working Group on Varicella (EuroVar). Consensus: Varicella vaccination of healthy children. A challenge for Europe. Pediatr Infect Dis J. 2004;23:379-89.
9. Siedler A, Arndt U. Impact of the routine varicella vaccination programme on varicella epidemiology in Germany. Euro Surveill. 2010;15:1-7.
10. Ramet J, Weil-Olivier C, Sedlak W. Is Europe ready to embrace a policy of universal varicella vaccination? Int J Clin Pract. 2005;59:1326-33.
11. Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA. 2002;287:606-11.
12. Impfplan Österreich 2013. Available at: http://bmg.gv.at/home/Schwerpunkte/Praevention/Impfen/Oesterreichischer-Impfplan-2013 [accessed 30 September 2013].
13. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/su6201a3.htm [accessed 30 September 2013].
14. National Advisory Committee on Immunization. Statement on the recommended use of herpes zoster vaccine. Canada Communicable Disease Report. 2010;36:ACS-1.
15. JCVI short statement on Herpes zoster vaccines. Available at: http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/jcvi/dh-094744 [accessed 30 September 2013].
16. Hope-Simpson RE. The nature of herpes zoster: A Long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9-20.
17. Bennett GJ, Watson PN. Herpes zoster and postherpetic neuralgia: Past, present and future. Pain Res Manag. 2009;14:275-82.
18. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500-7.
19. van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine. 2011;29:2411-20.
20. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: A review. J Infect Dis. 2008;197 Suppl 2:224-7.
21. Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: A systematic multidisciplinary review. PLos One. 2013;8:e66485.
22. The World Bank: High income: OECD. Available at: http://data.worldbank.org/income-level/OEC [accessed 30 September 2013].
23. Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment. A review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355-71.
24. Organisation for Economic Co-operation and Development (OECD): Consumer price indices and purchasing power parities. Available at: http://data.oecd.org/ [accessed 30 September 2013].
25. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
26. Najafzadeh M, Marra CA, Galanis E, Patrick DM. Cost effectiveness of herpes zoster vaccine in Canada. Pharmacoeconomics. 2009;27:991-1004.
27. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Hongyuan Zhang J, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271-84.
28. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann Intern Med. 2006;145:317-25.
29. Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis. 2008;197 Suppl 2:156-64.
30. Bilcke J, van Hoek AJ, Beutels P. Childhood varicella-zoster virus vaccination in Belgium. Cost-effective only in the long run or without exogenous boosting? Hum Vaccin Immunother. 2013;9:812-22.
31. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20:1113-25.
32. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88:862-9.
33. van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30:1225-34.
34. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine. 2000;18:407-145.
35. Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 2003;21:1256-67.
36. Bonanni P, Boccalini S, Bechini A, Banz K. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: The burden of uncomplicated hospitalised cases. Vaccine. 2008;26:5619-26.
37. Beutels P, Clara R, Tormans G, van Doorslaer E, van Damme P. Costs and benefits of routine varicella vaccination in German children. J Infect Dis. 1996;174 Suppl 3:335-41.
38. Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30:675-84.
39. Ultsch B, Weidemann F, Reinhold T, Siedler A, Krause G, Wichmann O. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013;13:359.
40. de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31:1276-83.
41. van Lier A, van Hoek AJ, Opstelten W, Boot HJ, de Melker HE. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.
42. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis. 2007;44:1280-8.
43. de Soárez PC, Novaes HMD, Sartori AMC. Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making? Cad Saude Publica. 2009;25 Suppl 3:401-14.
44. Thiry N, Beutels P, van Damme P, van Doorslaer E. Economic evaluations of varicella vaccination programmes. A review of the literature. Pharmacoeconomics. 2003;21:13-38.
45. Rozenbaum MH, van Hoek AJ, Vegter S, Postma MJ. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines. 2008;7:753-82.
46. Unim B, Saulle R, Boccalini S, Taddei C, Ceccherini V, Boccia A, Bonanni P, La Torre G. Economic evaluation of Varicella vaccination: results of a systematic review. Hum Vaccin Immunother. 2013;9:1932-42.
47. Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics. 2013;31:125-36.
48. Hudečková H, Straka S, Rusňáková S. Epidemiological features and economic evaluation of a potential chickebpox vaccination strategy in Slovac Republic. Cent Eur J Public Health. 2000;8:227-8.
49. Gialoretti LG, Divizia M, Pica F, Volpi A. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the latin region of Italy. Herpes. 2005;12:33-7.
50. Goeree R, Burke N, O'Reilly D, Manca A, Blackhouse G, Tarride J-E. Transferability of economic evaluations: approaches and factors to cionsider when using results from one geographic area for another. Curr Med Res Opin. 2007;23:671-82.
51. Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin. 2009;5:847-57.
52. Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 1999;17:142-51.
53. Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy. An economic evaluation of different scenarios. Pharmacoeconomics. 2004;22:839-55.
54. Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8:209-22.
55. Díez Domingo J, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine. 1999;17:1306-11.
56. Getsios D, Caro JJ, Caro G, de Wals P, Law BJ, Robert Y, Lance JR. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr Infect Dis J. 2002;21:542-7.
57. Ginsberg GM, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect. 2004;48:119-33.
58. Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: An economic analysis. Vaccine. 2007;25:7307-12.
59. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: An analysis of benefits costs. J Pediatr. 1994;124:869-74.
60. Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain - Results from a dynamic model. Vaccine. 2006;24:6980-9.
61. Lieu TA, Cochi SL, Black SB, Halloran E, Shinefield HR, Holmes SJ, Wharton M, Washington E. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 1994;271:375-81.
62. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad Med J. 1985;61 Suppl 4:17-22.
63. Scuffham P, Devlin N, Eberhardt-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc Sci Med. 1999;49:763-79.
64. Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, van Damme P. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine. 2004;22:3546-62.
65. Annemans L, Bresse X, Gobbo C, Papageorgiou M. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and postherpetic neuralgia in adults in Belgium. J Med Econ. 2010;13:537-51.
66. Bresse X, Annemans L, Préaud E, Bloch K, Duru G, Gauthier A. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2013;13:393-406.
67. Brisson M, Pellissier JM, Camden S, Quach C, de Wals P. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin. 2008;4:238-45.
68. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19:3076-90.
69. Moore L, Remy V, Martin M, Beillat M, McGuire A. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Eff Resour Alloc. 2010;8:7.
70. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25:8326-37.
71. Szucs TD, Kressig RW, Papageorgiou M, Kempf W, Michel J, Fendl A, Bresse X. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7:749-56.
72. van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27:1454-67.